Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NGM offers trading in Ether tracker from Vontobel

Starting today, Vontobel lists Ether trackers at NGM under the short name Track Ether VON.The tracker enables investors to participate in the Ether price performance without buying and storing Ether digitally. In addition, the tracker makes Ether a securitized financial instrument, which can be traded simply and transparently on the Swedish NGM Exchange. ”It is with great pleasure we list this Ether product from Vontobel. It is the first product on Ether on NGM and it has a big interest among investors. This listing further strengthens the crypto products offering at NGM.” says Tommy

Tecnotree Corporation –Managers’ transactions (Kaj Hagros)

Tecnotree CorporationManages’ Transactions23 May 2019 at 9:45 am (EEST)Person subject to the notification requirementName: Hagros, Kaj PeterPosition: Member of the BoardIssuer: Tecnotree OyjLEI: 743700MRPVY17ASHCX38 Notification type: INITIAL NOTIFICATION Reference number: 743700MRPVY17ASHCX38_20190521164055_2 ____________________________________________ Transaction date: 2019-05-16 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009010227 Nature of the transaction: ACQUISITION Transaction details (1): Volume: 8,965 Unit price: .

Hunter Group ASA: Private placement successfully completed

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.23 May 2019 Reference is made to the stock exchange notice released by Hunter Group ASA (the "Company", ticker HUNT) on 22 May 2019 regarding a contemplated private placement (the "Private Placement") of new shares in the Company. The Company is pleased to announce that

Klaria announces positive pre-clinical proof-of-concept study results with the Cannabinoid CBD, superior data on both tested outcome measures demonstrated

Today, Klaria announces positive results in a pre-clinical Proof-of-Concept (PoC) study conducted with the cannabinoid CBD, formulated in the company’s proprietary alginate transmucosal film.  The results demonstrate that Klaria’s technology has the potential to significantly improve the delivery of cannabis-derived compounds, particularly with respect to rapid, exact and reproducible dosing. As such, it could be of great benefit to patients and other stakeholders across the cannabis industry.The PoC study was positive on both key measures, which were 1) time to clinically/medically

PMS & PMDD in spotlight at Gothenburg event for International Menstrual Hygiene Day

(Stockholm May 23, 2019) Valuable knowledge about PMS & PMDD will be shared at the University of Gothenburg on May 28 at a public evening of talks, lectures and Q&A. Prof Torbjörn Bäckström, PMDD research pioneer and Asarina Pharma CSO, will speak about the science and treatment of PMDD.The PMS & PMDD evening will take place at the University of Gothenburg, Sprängkullsgatan 19, 1700-1930. It has been organised by Isabel Lindström of the Gender Equality organisation Bättre än de flesta, together with the organisation Mensen. Over a hundred are expected to attend the event, which is being

Sale of vessel

Farstad Shipping Pte. Ltd., a wholly owned subsidiary of Solstad Offshore ASA, has sold the PSV Lady Melinda (built 2003, 5.454 BHP). Delivery of the vessel to the new owner took place today Thursday May 23rd, 2019.  The sale of the vessels will result in an immaterial accounting effect for 2Q 2019. Skudeneshavn, May 23rd, 2019 ContactsLars Peder Solstad CEO, at +47 91 31 85 85Anders Hall Jomaas CFO, at +47 40 04 29 18 Solstad Offshore ASAwww.solstad.com This information is subject of the disclosure requirements according to the Norwegian Securities Trading Act section

Correction: Interim Report 1 January - 31 March 2019

This is a correction of the announcement from 11:26 22.05.2019 CEST. Reason for the correction: page “Liabilities and equity” was missing. Interim report enclosed in full length. Risk Intelligence A/S (“Risk Intelligence” or "the Company") hereby publishes the Q1 Interim Report for the period January - March 2019, which reports a 78% increase in revenue compared to Q1 2018. The report is available on the Company’s website (www.riskintelligence.eu).·         Revenue: TDKK 3,199 (1,802) ·         Earnings before interest, taxes, depreciation and amortization (EBITDA): TDKK -2,367 (-937)

SFC Holding S.à.r.l. has sold shares in Cibus Nordic Real Estate AB (publ) amounting to approximately SEK 1.1bn

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.The largest shareholder in Cibus Nordic Real Estate AB (publ) ("Cibus" or the "Company"), SFC Holding S.à.r.l. (the “Selling Shareholder”) has sold 9,644,443 shares, corresponding to

1st Quarter 2019

Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016.  +--------------------------------------------------------+|First Quarter (2019-01-01 – 2019-03-31) |+--------------------------------------------------------+| || · Net revenues were TDKK 0 (0) || · EBIT was TDKK -1,463 (-3,111) || · Earnings per share was DKK –0.06 (-

Klaria Pharma Holding Quarterly Report Q1 2019

Klaria Pharma Holding Quarterly Report Q1 2019Encouraging progress in Klaria’s cannabinoid program First three months of the year (January – March) Net sales 3,8 MSEK (0,0 MSEK) R&D costs for the period amounted to 4,8 MSEK (5,1 MSEK) Net income for the period amounted to -2,1 MSEK (-6,2 MSEK) Earnings per share amounted to -0,07 SEK (-0,20 SEK) Cash flow from operations amounted to 0,8 MSEK (-3,7 MSEK) Cash and cash equivalents on the balance day amounted to 8.7 MSEK (13.4 MSEK) Shareholder’s equity per March 31, 2019 amounted to 92.6 MSEK (115.8 MSEK)

Tele2 has agreed with Kazakhtelecom on the terms of its exit from Kazakhstan

Stockholm – Tele2 AB (“Tele2”) (Nasdaq Stockholm: TEL2 A and TEL2 B) has agreed with Kazakhtelecom on the price for its equity share in the joint venture between Tele2 and Kazakhtelecom (“the JV”). The net proceeds to Tele2, after deducting the existing earn-out liability, will be USD 169 million (approximately SEK 1.6 billion). In addition Tele2 will receive full repayment of its shareholder loan amounting to KZT 80 billion (approximately SEK 2.1 billion). The transaction is expected to close at the end of June.– Tele2 has built a successful business in Kazakhstan and rolled out a national

Interim Report 01/01/2019 – 31/03/2019

Summary of quarter Q1 2019 The following summary refers to the period 01/01/2019 – 31/03/2019, compared to 01/01/2018 – 31/03/2018 · Net sales for this period totaled to SEK 333,620 (SEK 0)  · Operating result for the period of SEK -1,980,615 (SEK -2,192,873) · Cash and bank balance SEK 3,701,727 (SEK 13,605,765) · Capitalized development costs of SEK 338,053 (SEK 404,996) · Average number of registered shares 9,877,264 (9,877,264 shares) · Result per share* SEK –0.20 (SEK -0.22) · Equity Ratio 74.8% (93.8%) *Result per share is calculated on the average

Interim Report Q1 2019

Negative impact from regulation effects in Europe, while North America continues to grow First quarter 2019 · Revenue from operations declined to EUR 4,053 (4,328) thousand. · EBITDA declined to EUR 2,553 (3,102) thousand. Adjusted for a one-time effect related to the divestment of the Battle of Malta, EBITDA for Q1 2018 was EUR 2,801 thousand. · Profit after tax declined to EUR 1,941 (2,144) thousand.  · Earnings per share after dilution fell to EUR 0.026 (0.031). · Total NDC growth declined by -15%; NDCs for largest vertical Casino declined by -14%. · Cash flow from

MAX’s menu grows with new innovation- Launches plant-based burger, Delifresh Plant Beef

  On May 23rd, MAX Burgers is launching a self-developed burger that looks and tastes like meat, but is made from plant-based protein: Delifresh Plant Beef. It’s a unique Swedish innovation that has been developed under the leadership of head chef Jonas Mårtensson. The initiative is a big step forward in MAX’s work to reduce its climate impact – without backing down on taste and quality. MAX’s goal is for 50 per cent of sold meals in 2022 to be comprised of something other than red meat, and to date, sales are close to 40 percent. Now the burger chain is stepping up both its

Targovax to fully focus on ONCOS oncolytic virus program

Oslo, Norway, 23 May 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that going forward the company will strengthen the commitment to oncolytic viruses and focus resources to advance the ONCOS program with full force.  With the reporting of encouraging median overall survival and three-year survival rate, the TG01 trial in resected pancreatic cancer has been successfully completed (see press release here ). The

Targovax announces median and three-year overall survival for TG01 trial in resected pancreatic cancer

Oslo, Norway, 23 May 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces median overall survival of 33.3 months and 38% three-year survival rate in the 32-patient phase I/II clinical trial evaluating TG01 in resected pancreatic cancer in combination with standard of care chemotherapy (gemcitabine).  Targovax has previously reported median overall survival (mOS) of 33.1 months for the 19 patients in the first dosing cohort, as well as 72% two-year survival rate and 94% mutant RAS-

YIT’s Sustainability Review 2018 published

YIT Corporation Press Release May 23, 2019 at 9:10 a.m.YIT’s Sustainability Review for 2018 has been published. The Review describes YIT’s sustainable operations and the achievements, targets and operating principles related to sustainable development. The Sustainability Review and its attachments are available on YIT’s website at www.yitgroup.com/en/sustainability/sustainability-review and also as attachments to this press release in Finnish and English.   The most important steps and highlights that YIT has taken in the field of sustainable development in 2018 have been collected to

SinterCast to confirm new series production and new installation activities at Annual General Meeting

[Stockholm, 23 May 2019] – At the SinterCast AB (publ) Annual General Meeting (AGM) to be held at 15:00 today, Dr Steve Dawson, President & CEO, will confirm new series production programmes and new installation activities for Compacted Graphite Iron (CGI) and for the company’s Tracking Technologies. Dr Dawson will comment on the recent growth from 2.5 million Engine Equivalents in 2018 to the new record level of 3.4 million Engine Equivalents in March 2019, and will confirm that April also finished at 3.4 million. Dr Dawson will express confidence in continued growth in each of the

InDex Pharmaceuticals presents at the Introduce Investor Days

May 23, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at the Introduce Investor Days at Haymarket by Scandic in Stockholm on May 27 at 9.30 CET.The event is hosted by ABG Sundal Collier and is open for both private and institutional investors. The presentation will also be livestreamed and can be followed at www.introduce.se. For more information:Peter Zerhouni, CEOPhone: +46 8 508 847 35E-mail: peter.zerhouni@indexpharma.com  InDex Pharmaceuticals in briefInDex is a pharmaceutical development company focusing

Landshypotek Bank’s AT1 instrument downgraded

S&P Global Ratings is downgrading Landshypotek Bank’s AT1 instrument from BB+ till BB.The downgrade of the AT1 instrument is a result of the implementation of the Swedish Financial Supervisory Authority's amended rules on mortgage risk weights, moving it from Pillar 2 to Pillar 1. Although this change does not directly affect the regulatory capital requirements in nominal terms of the bank, nor S&P’s measure of risk-adjusted capital and overall creditworthiness of the bank, it reduces the regulatory capital ratios. According to S&Ps criteria the bank should have a buffer of 700 basis

Helén Lindskog new Business Controller at Catena

Helén Lindskog is the new Business Controller at Catena, a strategically important role focusing on profitability analysis, valuation and investment monitoring.23 May 2019, 8:00 a.m.   Helén’s background is in the banking sector, most recently in the position of Customer Analyst at Swedbank, where listed property groups were her principal focus. The role of Business Controller at Catena is strategically important for the operations from both a business and financial perspective. “With her substantial expertise, Helén will be able to provide valuable support both to Catena’s management

Notice of the Extraordinary General Meeting in Boozt AB

The shareholders in Boozt AB, Reg. No. 556793-5183, are hereby invited to attend the extraordinary general meeting (Sw. extra bolagsstämma) to be held at the offices of Setterwalls Advokatbyrå AB, Stortorget 23 in Malmö, Sweden, on Monday 24 June 2019 at 10.00 a.m.The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Right to participate in the meeting and notice of participation Shareholders wishing to attend the meeting must: · be registered in the company’s share

Bactiguard receives research grant from Vinnova for developing vascular stents

In collaboration with researchers at Karolinska Institute, Bactiguard has been awarded a research grant of SEK 1.5 million for the development of noble metal-coated stents. The purpose of the project is to reduce the risk of thrombosis in connection with interventions in the bloodstream.“Stents save lives and are used in both acute care and as a preventive measure of for example heart infarction and stroke. At the same time, the treatment leads to a greatly increased risk of thrombosis formation (blood clotting) in the stent, which is currently managed by prescribing the patient double

There are no items matching the current filter
There are no more items matching the current filter
Back to top